- Home
- GALT vs VNDA Comparison
GALT vs VNDA Comparison
Compare GALT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- VNDA
- Stock Information
- Founded
- GALT 2000
- VNDA 2002
- Country
- GALT United States
- VNDA United States
- Employees
- GALT N/A
- VNDA N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- VNDA Health Care
- Exchange
- GALT Nasdaq
- VNDA Nasdaq
- Market Cap
- GALT 232.3M
- VNDA 249.4M
- IPO Year
- GALT N/A
- VNDA 2006
- Fundamental
- Price
- GALT $4.60
- VNDA $4.61
- Analyst Decision
- GALT Strong Buy
- VNDA Strong Buy
- Analyst Count
- GALT 3
- VNDA 2
- Target Price
- GALT $6.00
- VNDA $16.50
- AVG Volume (30 Days)
- GALT 241.8K
- VNDA 460.3K
- Earning Date
- GALT 08-14-2025
- VNDA 11-05-2025
- Dividend Yield
- GALT N/A
- VNDA N/A
- EPS Growth
- GALT N/A
- VNDA N/A
- EPS
- GALT N/A
- VNDA N/A
- Revenue
- GALT N/A
- VNDA $203,467,000.00
- Revenue This Year
- GALT N/A
- VNDA $15.45
- Revenue Next Year
- GALT N/A
- VNDA $37.82
- P/E Ratio
- GALT N/A
- VNDA N/A
- Revenue Growth
- GALT N/A
- VNDA 11.78
- 52 Week Low
- GALT $0.73
- VNDA $3.81
- 52 Week High
- GALT $4.71
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- GALT 69.41
- VNDA 51.38
- Support Level
- GALT $3.93
- VNDA $4.54
- Resistance Level
- GALT $4.35
- VNDA $4.92
- Average True Range (ATR)
- GALT 0.27
- VNDA 0.19
- MACD
- GALT 0.03
- VNDA 0.02
- Stochastic Oscillator
- GALT 91.67
- VNDA 38.00
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.